12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Hyperion sales and marketing update

On a Feb. 4 conference call regarding FDA's approval of Ravicti glycerol phenylbutyrate, Hyperion said it estimated a mean gross price of $250,000-$290,000 annually per patient for the drug. Company management said that about 40% of patients are on Medicaid, which includes a 23% rebate....

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >